The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology

Pharmacology

Fei Lin¹  Peng Jiang²  Ning Shi³  Jingyue Qiu³  Dandan Sheng³ 

[1] Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China;Clinical Medical College, Chengdu Medical College, Chengdu, China;Medical Team, PLA Strategic Support Force Integrated Training Team, Beijing, China;Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, China;

关键词: CDK4/6 inhibitor;    trilaciclib;    chemotherapy;    myelosuppression;    meta-analysis;   

DOI  :  10.3389/fphar.2023.1157251

 received in 2023-02-02, accepted in 2023-05-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background: This study aims to assess the clinical efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane Library, Clinical Trials, EU Clinical Trials Register, and International Clinical Trials Registry Platform were searched up to 25 October 2022. Only randomized controlled trials (RCTs) comparing the clinical outcomes of Trilaciclib and Trilaciclib plus chemotherapy for treating malignant cancers in adult patients were included. The primary outcome included the incidence of SN, FN, the DSN, and administration of ESAs, G-CSFs, and RBC or platelet transfusions, while the secondary outcomes included the risk of adverse events (AEs) and severe adverse events (SAEs).Results: In total, four randomized controlled trials (RCTs) involving 345 patients with SCLC or breast cancer were included in this meta-analysis. Results showed that administration of Trilaciclib significantly reduced the occurrence of SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. The proportion of patients receiving therapeutic use of ESAs (4.03% vs. 11.8%, OR = 0.31), G-CSF (37.0% vs. 53.5%, OR = 0.52), RBC transfusions (19.8% vs. 29.9%, OR = 0.56) was also statistically lower in the experimental group than in the control group. Meanwhile, the ORR, overall survival, and progress-free survival of the two groups were identical, and no negative impact of Trilaciclib on the clinical outcomes of chemotherapy treatments was found. Other chemotherapy-induced adverse events (AEs) and severe adverse events (SAEs) like diarrhea, fatigue, nausea, and vomiting were identical regardless of Trilaciclib usage.Conclusion: Trilaciclib demonstrated its efficacy in reducing the occurrence of chemotherapy-induced myelosuppression and utilization of supportive care interventions without undermining the clinical benefits of chemotherapy regimens during treatment with an acceptable safety profile.

【 授权许可】

Unknown   
Copyright © 2023 Qiu, Sheng, Lin, Jiang and Shi.